---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-007938"
form_type: "8-K"
ticker: "BTCY"
cik: "0001630113"
company_name: "BIOTRICITY INC."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:55:38.406814+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biotricity Q3 FY25 revenue $3.6M (+21.7% YoY); net loss down 56.7% to $1.32M

## Summary
- Gross margin improved to 76.4% from 72.9% YoY; recurring tech fees 94% of revenue at 81.4% gross profit.
- Recurring Technology Fees rose 21.8% YoY to $3.39M; pure SaaS revenue up 22%.
- SG&A reduced 20.5% to $2.38M from $3.0M; positive cash flow from operations second consecutive quarter, up 114.5% sequentially.
- Net loss per share improved to $0.054 from $0.339 in Q3 FY24.

## SEC filing metadata
- accession: 0001493152-25-007938
- form_type: 8-K
- ticker: BTCY
- cik: 0001630113
- company_name: BIOTRICITY INC.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630113/000149315225007938/0001493152-25-007938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630113/000149315225007938/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-007938
- JSON: https://secwatch.observer/filing/0001493152-25-007938.json
- Plain text: https://secwatch.observer/filing/0001493152-25-007938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.